Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 11,600 shares, an increase of 152.2% from the September 30th total of 4,600 shares. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is presently 0.9 days.
Genenta Science Price Performance
Shares of GNTA traded down $0.13 during trading hours on Friday, hitting $5.22. The company’s stock had a trading volume of 8,137 shares, compared to its average volume of 29,437. The business has a 50 day simple moving average of $4.49 and a two-hundred day simple moving average of $3.87. Genenta Science has a 52-week low of $2.20 and a 52-week high of $7.28.
Institutional Investors Weigh In On Genenta Science
An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new position in Genenta Science S.p.A. (NASDAQ:GNTA – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent SEC filing. Hedge funds and other institutional investors own 15.13% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on GNTA
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
See Also
- Five stocks we like better than Genenta Science
- Dividend Payout Ratio Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 5 Top Rated Dividend Stocks to Consider
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Health Care Stocks Explained: Why You Might Want to Invest
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.